Literature DB >> 23242980

Low-dose human atrial natriuretic peptide for the prevention of postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery.

Takashi Nojiri1, Masayoshi Inoue, Hajime Maeda, Yukiyasu Takeuchi, Noriyoshi Sawabata, Yasushi Shintani, Kazuhiro Yamamoto, Meinoshin Okumura.   

Abstract

OBJECTIVES: Lung cancer patients with chronic obstructive pulmonary disease are at an increased risk of respiratory and cardiovascular complications after pulmonary resection. The objective of the present study was to evaluate the clinical effects of low-dose human atrial natriuretic peptide (hANP) on postoperative cardiopulmonary complications in untreated chronic obstructive pulmonary disease patients undergoing lung cancer surgery.
METHODS: Of 824 patients who underwent an elective pulmonary resection procedure for lung cancer in two specialized thoracic centres between 2008 and 2011, 202 consecutive patients who had airflow limitation before surgery were included in this retrospective study. The results were compared between patients who did and those who did not receive hANP during the perioperative period. The primary endpoint was the incidence of postoperative cardiopulmonary complications. Postoperative haemodynamics, white blood cell (WBC) counts and C-reactive protein (CRP) levels were also examined. Furthermore, propensity score matching analysis was used to reduce treatment selection bias from patient characteristics.
RESULTS: The incidence of postoperative cardiopulmonary complications was significantly lower in the hANP group than in the control group (14 vs 36%, P < 0.01). The propensity score matching analysis confirmed the significantly decreased frequency of postoperative cardiopulmonary complications in the hANP group. Patients in the hANP group showed significantly lower WBC counts and serum CRP levels postoperatively.
CONCLUSIONS: Treatment with hANP during the perioperative period had a prophylactic effect against postoperative cardiopulmonary complications in chronic obstructive pulmonary disease patients undergoing lung cancer surgery.

Entities:  

Keywords:  Lung cancer surgery; Perioperative care; Postoperative complications

Mesh:

Substances:

Year:  2012        PMID: 23242980     DOI: 10.1093/ejcts/ezs646

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  7 in total

1.  B-type natriuretic peptide-guided risk assessment for postoperative complications in lung cancer surgery.

Authors:  Takashi Nojiri; Masayoshi Inoue; Yasushi Shintani; Yukiyasu Takeuchi; Hajime Maeda; Toshimitsu Hamasaki; Meinoshin Okumura
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

2.  Status of coexisting chronic obstructive pulmonary disease and its clinicopathological features in patients undergoing lung cancer surgery: a cross-sectional study of 3,006 cases.

Authors:  Xiang-Lin Hu; Song-Tao Xu; Xiao-Cen Wang; Dong-Ni Hou; Cui-Cui Chen; Dong Yang; Yuan-Lin Song
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

3.  Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells.

Authors:  Takashi Nojiri; Hiroshi Hosoda; Takeshi Tokudome; Koichi Miura; Shin Ishikane; Kentaro Otani; Ichiro Kishimoto; Yasushi Shintani; Masayoshi Inoue; Toru Kimura; Noriyoshi Sawabata; Masato Minami; Tomoyuki Nakagiri; Soichiro Funaki; Yukiyasu Takeuchi; Hajime Maeda; Hiroyasu Kidoya; Hiroshi Kiyonari; Go Shioi; Yuji Arai; Takeshi Hasegawa; Nobuyuki Takakura; Megumi Hori; Yuko Ohno; Mikiya Miyazato; Naoki Mochizuki; Meinoshin Okumura; Kenji Kangawa
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-16       Impact factor: 11.205

4.  A multicenter randomized controlled trial of surgery alone or surgery with atrial natriuretic peptide in lung cancer surgery: study protocol for a randomized controlled trial.

Authors:  Takashi Nojiri; Haruko Yamamoto; Toshimitsu Hamasaki; Kaori Onda; Kikuko Ohshima; Yasushi Shintani; Meinoshin Okumura; Kenji Kangawa
Journal:  Trials       Date:  2017-04-20       Impact factor: 2.279

5.  Atrial natriuretic peptide protects against bleomycin-induced pulmonary fibrosis via vascular endothelial cells in mice : ANP for pulmonary fibrosis.

Authors:  Atsuko Okamoto; Takashi Nojiri; Kazuhisa Konishi; Takeshi Tokudome; Koichi Miura; Hiroshi Hosoda; Jun Hino; Mikiya Miyazato; Yohkoh Kyomoto; Kazuhisa Asai; Kazuto Hirata; Kenji Kangawa
Journal:  Respir Res       Date:  2017-01-03

Review 6.  Management of atrial fibrillation in patients taking targeted cancer therapies.

Authors:  Aarti Asnani; Anastasia Manning; Moussa Mansour; Jeremy Ruskin; Ephraim P Hochberg; Leon M Ptaszek
Journal:  Cardiooncology       Date:  2017-03-09

7.  Transcriptome analysis reveals a role for the endothelial ANP-GC-A signaling in interfering with pre-metastatic niche formation by solid cancers.

Authors:  Takashi Nojiri; Miki Arai; Yutaka Suzuki; Motofumi Kumazoe; Takeshi Tokudome; Koichi Miura; Jun Hino; Hiroshi Hosoda; Mikiya Miyazato; Meinoshin Okumura; Shinpei Kawaoka; Kenji Kangawa
Journal:  Oncotarget       Date:  2017-05-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.